GlassScriptPhysician profile
Lisa Draucikas
NPI 1003243981
$1,636.05
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $152 · 2021: $300 · 2022: $623 · 2023: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.04 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $195.69 | 2021-2023 | Vraylar, Qulipta |
| Amgen INC. | $181.42 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.26 | 2019-2022 | |
| Abbott Laboratories | $128.03 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $99.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $80.73 | 2019-2023 | Belsomra, Segluromet, Steglujan |
| Genentech USA, INC. | $52.91 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.30 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.20 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $28.53 | 2019-2021 | |
| Pfizer INC. | $28.16 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.91 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.62 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $24.64 | 2019 | |
| Exact Sciences Corporation | $22.89 | 2023 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $16.34 | 2023 | Adthyza |
| Gilead Sciences, INC. | $14.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.00 | 2022 | |
| Dynavax Technologies Corporation | $9.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Draucikas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.